SCHEMBL10108994

SCHEMBL10108994

CCOC(=O)C[C@H]1CCCC[C@H]1c1ccc(OC)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
GAA P10253 3/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KMT2A Q03164 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 1/20 0.43
HDAC8 Q9BY41 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
HDAC1 Q13547 1/20 0.41
EPHX2 P34913 1/20 0.41
MEN1 O00255 3/20 0.41
HTT P42858 1/20 0.41
TSHR P16473 1/20 0.41
BRD4 O60885 2/20 0.41
HTR2C P28335 1/20 0.40
POLB P06746 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316990 1.00 ALDH1A1 (0.44) ALDH1A1GAAKDM4ELMNAHPGD
SCHEMBL10109196 0.87 SMN1; SMN2 (0.43) ALDH1A1KDM4ELMNAHPGDKMT2A
SCHEMBL10108800 0.85 HTR2A (0.46) ALDH1A1KDM4ELMNAMAPTTSHR
SCHEMBL317931 0.85 HTR2A (0.46) ALDH1A1KDM4ELMNAMAPTTSHR
SCHEMBL2437089 0.85 HTR2C (0.54) ALDH1A1GAAKDM4ELMNAHPGD
SCHEMBL15797925 0.85 HTR2C (0.54) ALDH1A1GAAKDM4ELMNAHPGD
SCHEMBL317936 0.84 SMN1; SMN2 (0.43) ALDH1A1HPGDKMT2ASMN1; SMN2HDAC8
SCHEMBL10108869 0.84 SMN1; SMN2 (0.43) ALDH1A1HPGDKMT2ASMN1; SMN2HDAC8
SCHEMBL317916 0.83 FFAR1 (0.46) ALDH1A1KMT2ASMN1; SMN2MAPTHDAC8
SCHEMBL10108998 0.83 FFAR1 (0.46) ALDH1A1KMT2ASMN1; SMN2MAPTHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093302-B2 Substituted tetralins as selective estrogen receptor-β agonists ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ESR2, ERLIN1, ESRRG ALDH1A1 1735/4885GAA 2018/4885KDM4E 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.